Themis Medicare Q4 FY26: Profitability Rebounds but Revenue Concerns Persist

The quarter's results present a mixed narrative for investors. Whilst the company has successfully returned to profitability after a challenging year-ago period marked by losses, the sequential revenue contraction of 15.09% and the sharp compression in operating margins from 10.86% in Q3 FY26 to 4.91% in Q4 FY26 raise questions about operational sustainability. The PAT margin of 11.62%, however, remained relatively stable, supported by significant non-operating income of ₹3.67 crores, which constituted 40.51% of profit before tax—a dependency that warrants investor scrutiny.

For the full year FY25, Themis Medicare reported net sales of ₹405.00 crores, representing a modest 6.30% growth over FY24's ₹381.00 crores. However, profit after tax for FY25 stood at ₹23.00 crores, a marginal decline from ₹24.00 crores in FY24, reflecting the operational challenges the company has faced throughout the year. The company's average return on equity of 14.31% and return on capital employed of 13.22% suggest moderate capital efficiency, though these metrics remain below industry leaders.

Quarterly Performance Trend: Volatility Defines Recent Quarters

The quarterly trend table reveals significant volatility in both revenue and profitability over the past seven quarters. After posting strong results in Sep'24 with sales of ₹117.01 crores and net profit of ₹14.29 crores, the company experienced consecutive quarters of losses in Jun'25 and Sep'25 before staging a recovery in the subsequent two quarters. This erratic performance pattern suggests operational instability and raises concerns about the company's ability to maintain consistent growth momentum.

Financial Performance Analysis: Margin Compression Amidst Revenue Decline

The Q4 FY26 quarter witnessed net sales of ₹76.53 crores, declining 15.09% sequentially from ₹90.13 crores in Q3 FY26, though showing a 6.74% year-on-year improvement over the loss-making Mar'25 quarter's ₹71.70 crores. This sequential revenue contraction represents a concerning trend, particularly when viewed against the 9.30% decline versus the previous four-quarter average.

The operating profit margin (excluding other income) compressed sharply to 4.91% in Q4 FY26 from 10.86% in Q3 FY26, a contraction of 595 basis points. Operating profit stood at ₹3.76 crores, down dramatically from ₹9.79 crores in the previous quarter. This margin deterioration, coupled with elevated employee costs of ₹21.06 crores (27.52% of sales), suggests significant operational challenges and potential pricing pressures in the pharmaceutical segment.

However, the company's bottom line benefited substantially from other income of ₹3.67 crores in Q4 FY26, nearly trebling from ₹1.28 crores in Q3 FY26. This non-operating income represented 40.51% of profit before tax, raising concerns about the sustainability of reported profitability. The standalone net profit of ₹1.96 crores contrasted sharply with the consolidated figure of ₹8.89 crores, indicating significant contributions from subsidiaries or other entities within the group structure.

Operational Challenges: Margin Pressure and Revenue Volatility

Themis Medicare's operational performance reveals structural challenges that extend beyond cyclical headwinds. The company's average return on equity of 14.31% over recent years, whilst positive, lags behind pharmaceutical sector leaders and reflects moderate capital efficiency. More concerning is the latest ROE of -7.10%, indicating that the company has been destroying shareholder value in the most recent period. Similarly, the average ROCE of 13.22% compares unfavourably with the sector's top performers, suggesting suboptimal asset utilisation.

The five-year sales growth of 9.43% appears respectable on the surface, but the five-year EBIT growth of -185.54% tells a starkly different story. This dramatic contraction in operating profitability over the medium term indicates that revenue growth has not translated into sustainable earnings expansion. Instead, the company appears to have faced persistent margin compression, likely driven by competitive pressures, raw material cost inflation, or operational inefficiencies.

From a balance sheet perspective, Themis Medicare maintains a relatively conservative capital structure with shareholder funds of ₹402.60 crores as of Mar'25, supported by reserves of ₹393.40 crores. Long-term debt stood at ₹18.61 crores, representing a manageable debt-to-EBITDA ratio of 0.30 and a net debt-to-equity ratio of 0.22. This low leverage provides financial flexibility but also suggests underutilisation of debt capital to drive growth.

Peer Comparison: Valuation Discount Reflects Concerns

Themis Medicare's peer comparison reveals a company trading at a significant valuation discount, though for justifiable reasons. With a trailing twelve-month loss position, the company lacks a meaningful P/E ratio, whilst its price-to-book value of 2.75x sits in the middle of the peer range. The company's ROE of 14.31% is respectable but trails higher-quality peers like Wanbury (42.23%) and Shukra Pharma (22.38%).

The company's conservative balance sheet, reflected in a debt-to-equity ratio of 0.22, provides downside protection but also suggests limited financial leverage to drive growth. The dividend yield of 0.44%, based on a latest dividend of ₹0.50 per share (ex-date: September 4, 2025), remains modest and reflects the company's cautious approach to capital allocation given recent profitability challenges.

Valuation Analysis: Risk Profile Limits Appeal

At the current market price of ₹114.60, Themis Medicare trades at a price-to-book value of 2.75x against a book value per share of ₹40.16. The company's valuation grade has deteriorated to "Risky" from "Attractive" in July 2025, reflecting the market's concerns about earnings sustainability and operational challenges. The negative EV/EBITDA multiple of -122.83x and EV/EBIT of -58.06x underscore the loss-making nature of recent trailing results.

The stock currently trades 25.80% below its 52-week high of ₹154.45 but 76.31% above its 52-week low of ₹65.00, suggesting it sits in the middle of its recent trading range. The company's enterprise value-to-sales ratio of 3.34x appears elevated given the operational challenges and margin pressures, particularly when compared against more profitable pharmaceutical peers.

With an overall Mojo score of 37 out of 100 and a "SELL" rating, the valuation framework suggests limited upside potential at current levels. The score reflects concerns across multiple dimensions: poor long-term EBIT growth (-185.54% five-year CAGR), underperformance versus the market (-18.14% one-year return against Sensex's -7.02%), and a bearish technical trend that shifted to "Mildly Bearish" in April 2026.

Shareholding Pattern: Stable Promoter Base with Minimal Institutional Interest

Themis Medicare's shareholding pattern reveals a stable promoter base holding 67.11% as of Mar'26, with the Vividhmargi Trust (27.49%), Vividhmargi Investments Pvt. Ltd. (26.52%), and Gedeon Richter Investment Management Ltd. (9.60%) forming the core promoter group. The absence of any sequential change in promoter holding over the past three quarters signals confidence in the company's long-term prospects, though 2.43% of promoter shares remain pledged.

The near-total absence of institutional investors represents a significant red flag. With FII holding at a mere 0.11%, zero mutual fund presence, and negligible insurance company or DII participation (0.01%), the company lacks the validation that typically comes with institutional scrutiny. This institutional vacuum suggests that larger, more sophisticated investors have not found the company's risk-reward profile attractive, likely due to the operational volatility and earnings inconsistency demonstrated over recent quarters.

Stock Performance: Short-Term Bounce Masks Long-Term Underperformance

Themis Medicare's stock performance presents a tale of two timeframes. Over the past three months, the stock has surged 32.79%, dramatically outperforming the Sensex's -6.62% decline and generating a positive alpha of 39.41%. This recent momentum, driven by a technical bounce from oversold levels near the ₹65.00 52-week low, has pushed the stock above all key moving averages—5-day (₹103.89), 20-day (₹99.77), 50-day (₹89.01), 100-day (₹88.62), and 200-day (₹101.47).

However, this short-term strength masks concerning longer-term underperformance. Over the past year, the stock has declined 18.14% against the Sensex's -7.02% fall, generating negative alpha of -11.12%. The two-year and three-year performance is even more troubling, with declines of 44.23% and 24.64% respectively, whilst the Sensex posted positive returns over the same periods. The stock has underperformed its pharmaceutical sector peers by 29.17 percentage points over the past year, with the sector returning +11.03% compared to Themis Medicare's -18.14%.

From a risk perspective, the stock exhibits high volatility (52.95%) with a beta of 1.32, indicating it moves 32% more than the broader market. The risk-adjusted return of -0.34 over the past year, compared to the Sensex's -0.54, places it in the "HIGH RISK LOW RETURN" category—an unfavourable combination for most investors. The current technical trend classification of "Mildly Bearish" since April 6, 2026, suggests caution despite the recent price bounce.

Investment Thesis: Quality Concerns Outweigh Turnaround Potential

Themis Medicare's investment thesis rests on fragile foundations. The company's quality grade of "Average" reflects a business that has struggled to demonstrate consistent operational excellence. Whilst the five-year sales growth of 9.43% appears reasonable, the five-year EBIT contraction of -185.54% reveals a fundamental inability to convert revenue into sustainable operating profits. The average ROCE of 13.22% and ROE of 14.31% remain below pharmaceutical sector benchmarks, indicating suboptimal capital deployment.

The financial trend turned "Positive" in Mar'26, driven by the sequential profit growth and turnaround from year-ago losses. However, this positive classification appears tenuous given the sharp revenue decline (-9.30% versus the four-quarter average) and the concerning dependency on non-operating income (40.51% of PBT). The lowest cash position in recent years (₹9.15 crores for the half-year) and deteriorating debtors turnover (1.92 times) suggest working capital pressures that could constrain near-term performance.

Outlook: What Lies Ahead for Themis Medicare